ArticleBMC microbiology2025
Novel antimicrobial strategy: native postbiotics synergize with antibiotics to overcome resistance in Klebsiella pneumoniae.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Beyond Probiotics: Postbiotics for Healthy Aquaculture.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Postbiotics as Multifunctional Bioactives: Mechanistic Insights and Translational Applications in Host Physiology and Microbial Ecosystem Modulation.Microorganisms · 2026Review
- Yeast-Derived Postbiotics for Prevention of Enteric Diseases in Farm Animals: Current Insights and Future Perspectives.Veterinary sciences · 2026Review
- Postbiotics at the interface of microbial biotechnology and therapeutics: industrial production, functional mechanisms, and clinical potentials.Archives of microbiology · 2026Review
- The gut reservoir of carbapenem-resistant Enterobacterales: from dysbiosis and colonization to infection and decolonization, with a focus on patients with hematologic malignancies - a narrative review.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe alarming rise of antimicrobial resistance (AMR), especially in Klebsiella pneumoniae, demands urgent development of novel therapeutic strategies. Recently, probiotics and their metabolites, known as postbiotics, have gained attention due to their potential to enhance antibiotic efficacy and combat resistant pathogens.
methodsIn this study, 88 native Lactobacillus spp. isolates, were screened for antimicrobial activity against a highly resistant K. pneumoniae ATCC 7881 strain with a minimum inhibitory concentration ≥ 2048 µg/mL. Based on screening results, four strains-Lactiplantibacillus plantarum RP155, 403, 225 and Ligilactobacillus salivarius RP317-were selected to produce postbiotics. Antimicrobial activity of these postbiotics, alone and combined with sub-inhibitory concentrations of amoxicillin and imipenem, was evaluated using the broth microdilution method. Gene expression of key antibiotic resistance determinants (bla
resultsAll postbiotics exhibited inhibitory effects on the growth of multidrug-resistant K. pneumoniae when applied in combination with low-dose antibiotics. Postbiotic concentrations ranging from 25 to 100 mg/mL combined with 1-4 µg/mL of amoxicillin or imipenem resulted in complete bacterial eradication. Molecular analyses revealed differential regulation of resistance genes: some postbiotics alone (notably L. plantarum RP225 and L. salivarius RP317) increased expression of specific resistance genes, whereas combinations with antibiotics significantly suppressed or completely silenced the expression levels of genes investigated.
conclusionOur findings demonstrate that native postbiotics, particularly in synergy with antibiotics, exert potent antimicrobial activity against multidrug-resistant K. pneumoniae and effectively downregulate critical resistance genes; highlighting the potential of postbiotics as adjunctive therapeutic agents in the battle against AMR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.